Bratodx (Encorafenib) 75mg Capsules | BRAF Inhibitor | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Bratodx (Laos)
Bratodx is a Laos-manufactured generic brand of encorafenib produced by Bigbear Pharmaceutical (Lao) Co., Ltd. It is supplied as 75 mg capsules in a 42-capsule box. Encorafenib is a BRAF kinase inhibitor that targets the BRAF V600E and V600K mutations driving a subset of melanomas, colorectal cancers and lung cancers. Bratodx offers the same encorafenib active ingredient as the originator at a more accessible cost, making long-course BRAF-targeted therapy more affordable.
What Is Bratodx (Encorafenib) Used For?
Bratodx is used for adults whose tumours carry a BRAF V600 mutation. Depending on the tumour type and the combination prescribed, encorafenib is used for BRAF V600-mutant melanoma, BRAF V600E-mutant metastatic colorectal cancer and BRAF V600E-mutant metastatic non-small cell lung cancer. A genomic test confirming the BRAF mutation is essential before treatment, since the medicine only acts on mutant BRAF.
How Does Encorafenib Work?
Encorafenib inhibits the mutant BRAF V600 kinase, switching off the overactive MAPK signalling cascade that promotes the growth of BRAF-mutant cancer cells. By interrupting this signal, the drug slows tumour growth and drives cancer-cell death while sparing normal cells. Used together with a MEK inhibitor such as binimetinib or with cetuximab, the pathway is blocked at two points, which deepens the response and helps delay resistance.
Indications
Encorafenib is indicated for BRAF-mutant cancers in specific combinations: with binimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, with binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer, and with cetuximab for BRAF V600E-mutant metastatic colorectal cancer after prior therapy. Encorafenib is not suitable for BRAF wild-type tumours and should be prescribed by an oncologist.
Dosage
The recommended dose of encorafenib depends on the indication: 450 mg (six 75 mg capsules) once daily for melanoma and lung cancer, and 300 mg (four 75 mg capsules) once daily for colorectal cancer, each with the prescribed partner drug. A 42-capsule box of Bratodx covers one week of treatment at the 300 mg dose. The prescribing physician may adjust the dose or schedule depending on tolerance and side effects, and patients should follow the treatment plan exactly.
Side Effects
Common side effects of encorafenib include fatigue, nausea, vomiting, diarrhoea, abdominal pain and reduced appetite. Skin reactions such as rash and itching, along with new skin lesions, are frequent and should be reviewed by a dermatologist. Patients may also notice fever, joint or muscle pain, headache and changes in liver enzymes or blood counts. New or changing skin growths, eye symptoms or unusual bleeding should be reported to the doctor promptly.
Storage
Keep Bratodx capsules at room temperature, away from moisture and heat, in their original box. Store out of the reach of children and do not use past the expiry date. No refrigeration is required.
Why Choose the GLT?
Bratodx delivers the same encorafenib active ingredient as the originator at a significantly lower price, which matters greatly for patients who need continuous, long-course BRAF-targeted therapy. Sourcing through GLT adds a dependable layer of verification — authenticity, current availability and proper export documentation — so institutions and individual patients can procure this Laos-manufactured generic with confidence and full traceability.
How to Order
To source Bratodx (encorafenib) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the quantity and your destination country, and we will confirm current stock, sourcing origin and the import documentation required. A valid prescription and BRAF-mutation test result are required, and we serve both institutions and individual patients.
FAQ
Is Bratodx the same as Braftovi? Bratodx is a generic brand of encorafenib, the same active ingredient as the originator Braftovi, manufactured by Bigbear Pharmaceutical in Laos.
Which cancers does encorafenib treat? Encorafenib is used for BRAF V600-mutant melanoma, BRAF V600E-mutant metastatic colorectal cancer and BRAF V600E-mutant metastatic non-small cell lung cancer in specific combinations.
Do I need a BRAF test before using Bratodx? Yes. A confirmed BRAF V600E or V600K mutation is required, as encorafenib does not work on BRAF wild-type tumours.
What pack size is Bratodx available in? Bratodx is supplied as 75 mg capsules in a 42-capsule box, covering one week of standard dosing.
Is a prescription required? Yes. Encorafenib is a prescription oncology medicine and must be used under an oncologist's supervision.